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INTRODUCTION 
A decade ago, the treatment of hypercholesterolemia and 
Hypertension was expected to eliminate CAD by the end of the 20th century. 
Lately, however, that optimistic prediction has needed revision. 
Cardiovascular diseases are expected to be the main cause of death globally 
Within the next 15 years owing to a rapidly increasing prevalence in 
Developing countries and Eastern Europe and the rising incidence of 
obesity, Diabetes and Diabetes related complication like chronic kidney 
disease (CKD) in both the developing world and the Western world (1). 
 Cardiovascular diseases cause 38 percent of all deaths in North 
America and are the most common cause of death in European men under 65 
Years of age and the second most common cause in women. These facts 
force us to revisit cardiovascular disease and consider new strategies for 
prediction, prevention, and treatment. 
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REVIEW OF LITERATURE 
Throughout the world Cardiovascular disease, End-stage renal disease 
and Diabetes mellitus are emerging as epidemics. Moreover, Contribution of 
one towards existence of others is alarming. Cardiovascular disease (CVD) 
is the leading cause of death in both patients with End- stage renal disease 
(ESRD) as well as in Diabetes mellitus (DM). With the shift in global effort 
from ‘Treating the disease’ to ‘Preventive medicine’ it is time to identify. 
The predisposing factors, modifiable and non modifiable factors that decide 
the occurrence of the killer disease – CVD, in its fertile soil – ESRD and 
DM.   
DIABETES AND CARDIOVASCULAR DISEASE 
 
A large body of epidemiological and pathological data documents that 
Diabetes is an independent risk factor for CVD in both men and Women. (3, 
4, 5). Diabetes is now perceived as ischemic heart disease equivalent 
.Women with diabetes seem to lose most of their inherent protection against 
developing CVD.(3, 6). CVDs are listed as the cause of Death in 65% of 
persons with Diabetes (7). Diabetes acts as an independent risk factor for 
several forms of CVD. To make matters worse, when patients with Diabetes 
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develop clinical CVD, they sustain a worse prognosis for survival than do 
CVD patients without Diabetes.(8, 9, 10). 
 
DIABETES AND RENAL DISEASE 
Renal disease is a common and often severe complication of Diabetes 
(12). Approximately 35% of patients with type 1 diabetes of 18 Years' 
duration will have signs of Diabetic renal involvement (13). Up to 35% of 
new patients beginning dialysis therapy have type 2 diabetes (14).  
Diabetes contributes signicantly to ESRD and it is almost the number 
one cause for renal failure in West. This same scenario is slowly appearing 
in our Indian subcontinent also; the budding Global capital of Diabetes. One 
in every three renal failure patients is a Diabetic. For patients with diabetes 
who are on renal dialysis, mortality rates probably exceed 20% per year 
(14). When diabetes is present, CVD is the leading cause of death among 
patients with ESRD(20, 21, 22).  
Detection of Clinical and Sub clinical CVD 
Prospective studies (23) document an increased likelihood of sudden 
cardiac death and unrecognized myocardial infarctions in patients with 
Diabetes. Moreover, acute ischemic syndromes, peripheral arterial disease, 
and advanced CVD complications occur more commonly in patients with 
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Diabetes than in those without (23). Because the typical cardiac symptoms 
often are masked in patients with diabetes, the diagnosis of Myocardial 
Infarction commonly is missed or delayed. Effective strategies for earlier 
detection of clinical CVD could reduce morbidity and mortality in patients 
with diabetes. 
 
In addition, detection of subclinical atherosclerosis and early clinical 
manifestation of CVD could lead to more effective primary prevention in 
some patients with diabetes(23). Noninvasive evaluation of cardiac function 
in hyperglycemic patients suspected of having myocardial dysfunction may 
be a useful guide to cardiovascular management in some of these patients. 
Many patients with diabetes suffer from an autonomic dysfunction that 
impairs quality of life and predisposes to life-threatening cardiovascular 
complications(23). Finally, the finding of subclinical CVD signals the need 
for institution of more aggressive preventive measures. 
Like Diabetes Mellitus, Chronic kidney disease itself is an 
independent risk factor for cardiovascular disease (26). 
CVD in CKD 
It is now becoming apparent that there is a high prevalence of CVD 
even in the earlier stages of CKD, and that CKD is a risk factor for CVD 
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[25]. Arterial vascular disease and cardiomyopathy are the primary types of 
CVD [25]. In CKD, it is useful to consider two subtypes of arterial vascular 
disease, namely atherosclerosis and arteriosclerosis or large vessel 
remodeling. Atherosclerosis is an intimal disease characterized by the 
presence of plaques and occlusive lesions. There is a high prevalence of 
atherosclerosis in CKD. Atherosclerotic lesions in CKD are frequently 
alcified, as opposed to fibroatheromatous, and have increased medial 
thickness in comparison with lesions in the general population (25). 
 
Patients with CKD also have a high prevalence of arteriosclerosis and 
remodeling of large arteries. Remodeling may be due either to pressure 
overload, which is distinguished by wall hypertrophy and an increased wall 
to lumen ratio, or flow overload, which is characterized by a proportional 
increase in arterial diameter and wall thickness(25). 
Patients with CKD also have a high prevalence of cardiomyopathy 
(25). Analogous to remodeling of largevessels, pressure overload leads to 
increased ratio of LV mass to diameter(concentric LVH), while volume 
overload leads to a proportional increase in LV mass and LV diameter (LV 
dilatation with LVH). 
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CLINICAL PRESENTATIONS OF CVD 
Atherosclerosis, Inducible ischemia, carotid IMT, EBCT (may be less 
useful than in the GP for atherosclerosis because of medial rather than 
intimal calcification), ischemiaIHD (myocardial infarction, angina, Sudden 
cardiac death), Cerebrovascular disease, PVD, HF, Arterial Vascular 
Disease(24, 25). 
CVD Risk Factors in CKD 
Traditional risk factors defined as those in the Framingham Heart 
Study that have been used to estimate the risk of developing symptomatic 
ischemic heart disease(29). Most of the traditional CVD risk factors, such as 
older age, diabetes mellitus, systolic hypertension, LVH, and low HDL 
cholesterol are highly prevalent in CKD(30). The cardiovascular risk 
conferred by many traditional risk factors, such as diabetes, older age, and 
LVH, largely parallels the relationships described in the general 
population(28). However, some important differences have been noted with 
regard to other risk factors. For example, “U” shaped relationships exist 
between all- cause mortality and both blood pressure and total cholesterol 
levels in dialysis patients(30, 31). Several studies have suggested that the 
Framingham risk equation is insufficient to capture the extent of CVD risk 
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in subjects with CKD [29- 32]. One explanation for these findings is that 
traditional risk factors may have qualitatively and/ or quantitatively different 
risk relationships with CVD in CKD, as compared to the general population. 
For example, individuals with CKD may have had a longer and more severe 
exposure to hypertension than subjects without CKD. In addition, subjects 
with CKD may have been treated for hypertension. 
The existing risk scores for cardiovascular diseases like the 
Framingham risk equation does not include the duration of exposure to risk  
factors nor treatment. Another explanation is that other factors (“ non- 
traditional” risk factors), which are not included in Framingham risk 
equations, may play an impor tant role in promoting ischemic heart disease 
in subjects with Diabetes and CKD(31). The non-traditional risk factors 
being elevated C- reactive protein(CRP), Von -willibrand factor, PAI-1, 
Interleukin-6.Of note, many of the hypothesized non-traditional risk factors 
are related to CKD(32).  
CRP IN ATHEROSCLEROSIS 
Highly sensitive C-Reactive protein (hs-CRP) 
hs C-reactive protein is an acute-phase reactant, synthesised primarily 
in the liver, that provides a measurement of low-grade systemic 
inflammation. 
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 In an attempt to improve global cardiovascular risk prediction, 
considerable interest has focused on hsCRP-, a marker of inflammation that 
has been shown in multiple prospective epidemiological studies to predict 
incident myocardial infarction, stroke, peripheral arterial disease, and sudden 
cardiac death. CRP levels have also been shown to predict risk of both 
recurrent ischemia and death among those with stable and unstable angina, 
those undergoing percutaneous angioplasty, and those presenting to 
emergency rooms with acute coronary syndromes. These highly consistent 
clinical data are supported by abundant laboratory and experimental 
evidence that demonstrate that atherothrombosis, in addition to being a 
disease of lipid accumulation, also represents a chronic inflammatory 
process. In terms of clinical application, hsCRP seems to be a stronger 
predictor of cardiovascular events than LDL cholesterol, and it adds 
prognostic information at all levels of calculated Framingham Risk and at all 
levels of the metabolic syndrome. 
Using widely available high-sensitivity assays, hsCRP levels of <1, 1  
to 3, and >3 mg/L correspond to low-, moderate-, and high-risk groups for 
future cardiovascular events. Individuals with LDL cholesterol below 130 
mg/dL who have CRP levels >3 mg/L represent a high-risk group often 
missed in clinical practice. The addition of hsCRP to standard cholesterol 
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evaluation may thus provide a simple and inexpensive method to improve 
global risk prediction and compliance with preventive approaches. 
 In the last few years hs C-reactive protein (CRP) has gained a lot of 
attention in the general population, especially with regard to its link with 
atherosclerosis. There are several studies to suggest that hsCRP may be 
useful as a parameter in predicting future cardiovascular events in both the 
general population and in patients with end-stage renal disease. A statistical 
association between hsCRP and cardiovascular disease was observed in 
various studies, the predictive power of this association is significant when 
adjusted for other risk factors(24).  
All stages of atherosclerotic disease may be considered an 
inflammatory response to injury that is promoted by the classic 
cardiovascular risk factors: atherogenic lipid profile, hyperglycaemia 
hypertension and smoking(24). 
With ongoing inflammation, macrophages are increased in umber and, 
after ingestion of oxidised lipids, become foam cells(27). Activated foam 
cells release hydrolytic enzymes, cytokines, growth factors and procoagulant 
substances. This results in the proliferation and migration of vascular smooth 
muscle causing further damage to the vascular system(27). Lesions are 
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enlarged and eventually form a fibromuscular cap, which reduces vascular 
compliance and results in hypertension; they may also rupture, resulting in 
myocardial infarction or stroke(3). 
The relative contributions of hsCRP as a marker, as a causative agent, 
and as a consequence of atherosclerotic vascular disease are clear now, both 
in the general population and in the diabetic and kidney disease patients(2).  
Comparison of hsCRP to Other Novel Risk Factors 
 hsCRP is not the only inflammatory biomarker that has been shown to 
predict myocardial infarction and stroke. More sophisticated measures of 
cytokine activity, cellular adhesion, and immunologic function (such as 
interleukin-6, intercellular adhesion molecule-1, macrophage inhibitory 
cytokine-1, and soluble CD40 ligand) have all been shown to be elevated 
among those at increased vascular risk.(37) These approaches, however, are 
unlikely to have clinical utility because the assays required for their 
assessment are either inappropriate for routine clinical use or the protein of 
interest has too short a half-life for clinical evaluation. Measures for 
fibrinogen, a biomarker involved in both inflammation and thrombosis, 
remain poorly standardized, and methodological issues limit use of this 
parameter despite consistent population-based data. Other broad measures of 
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systemic inflammation, such as the white blood cell count or the erythrocyte 
sedimentation rate, have proven unreliable in clinical settings. By contrast, 
high-sensitivity assays for CRP have been standardized across many 
commercial platforms. Moreover, hsCRP is highly stable, allowing measures 
to be made accurately in both fresh and frozen plasma without requirements 
for special collection procedures. This is due in part to the stable pentraxin 
structure of hsCRP and its long plasma half-life of 18 to 20 hours.  
 In selected patients, such as those with markedly premature and 
unexplained atherosclerosis, evaluation of other markers, such as 
lipoprotein(a) and homocysteine, may have clinical utility. In available 
population-based studies, however, the relative magnitude of these 
biomarkers has been small in direct comparison to hsCRP. Recent data also 
indicate that hsCRP is a stronger predictor of risk than nuclear magnetic 
resonance-based evaluation of LDL particle size and concentration.(38). 
Clinical Trials Data 
• hsCRP is the strongest marker of risk for future vascular events 
compared with 12 reported risk factors, including cholesterol [NEJM 
342:836-43]  
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• hsCRP distinguishes between low and high-risk patients, even in those 
with LDL-C below 130mg/dL (– a safe level according to current 
guidelines). [Intern Med 252:283-94] 
• hsC-reactive protein is a relatively moderate predictor of coronary heart 
disease, adding to the predictive value of established risk factors such as 
total serum cholesterol. [NEJM 350: 1387-1397] 
• Elevated serum levels of hsCRP predict risk for plaque rupture. 
[NEJM340:115-26] 
• High hsCRP has been associated with restenosis after percutaneous 
coronary intervention. [J Am Coll Cardiol 38:2006-12] 
• hsCRP is easily and inexpensively measured with standardised high-
sensitivity assays, with a range for risk detection that is comparable with 
total cholesterol. hsCRP rapidly increases in response to injury and 
inflammation by as much as 1000 times, declining to baseline levels 
within 7–10 days. 
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Risk Categories based on hsCRP level  
(Results are always expressed in mg/L) 
Relative Risk Category Average hs-CRP level 
Low < 1 mg/L 
Average 3.0 to 5.0 mg/L 
High > 5.0 mg/L 
 
There are currently number of prospective studies to demonstrate the 
benefits of screening for hsCRP. However, intermediate risk patients (10-
20% risk over 10 years) and those with the metabolic syndrome, diabetes, 
CKD may be more appropriate targets(4).Furthermore, there is a larger 
absolute risk reduction in treating people with elevated hsCRP, which 
demonstrates the potential utility of hsCRP in primary prevention and as a 
marker [NEJM 344:1959-65]. 
Interpreting hsCRP Assays, and Cost-Effectiveness 
In most clinical settings, a single hsCRP assessment is likely to be 
adequate as long as levels less than 10 mg/L are observed. Because major 
infections, trauma, or acute hospitalizations can elevate hsCRP levels 
(usually 100-fold or more), levels greater than 10 mg/L should initially be 
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ignored and the test repeated at a future date when the patient is clinically 
stable. 
Many investigators have recommended 2 measures of hsCRP, with 
the lower value or the average being used to determine vascular risk, a 
practice consistent with recommendations for cholesterol evaluation. 
 In rare instances where levels of hsCRP are markedly elevated, 
alternative sources of systemic inflammation such as lupus, inflammatory 
bowel disease, or endocarditis should be considered. In such cases, there is 
usually an accompanying elevation in the erythrocyte sedimentation rate. 
Accumulated experience in outpatient settings has shown such values to be 
infrequent. Because hsCRP levels are stable over long periods of time, are 
not affected by food intake, and demonstrate almost no circadian variation, 
there is no need to obtain fasting blood samples for hsCRP assessment. 
Despite being an acute phase reactant, the variability in hsCRP levels in 
given individuals is quite similar to that associated with cholesterol 
screening, as long as the hsCRP levels are within the clinical range defined 
above.(39) Traditional assays for hsCRP do not have adequate sensitivity to 
detect levels required for vascular disease prediction. 
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To alleviate this problem, high-sensitivity CRP assays have been 
developed and are now widely available.(40) The cost of hsCRP screening is 
comparable to that of standard cholesterol evaluation and far less than 
almost all other alternative approaches to cardiovascular screening under 
consideration. 
Both in terms of years of life saved and cost-to-benefit ratios, hsCRP 
screening seems to be highly effective.(41) In many settings, the approach of 
adding hsCRP to LDL screening may yield immediate cost-savings in terms 
of negative predictive value and the subsequent avoidance of unnecessary 
clinical testing, particularly when compared with far more expensive 
screening approaches such as electron beam calcium tomography 
or MRI. CRP levels within the range detected with high-sensitivity assays 
have demonstrated specificity for vascular events.(42) Although it has not 
been determined whether serial hsCRP assessment provides incremental 
clinical value, some physicians have elected to use hsCRP as part of their 
annual physical examination. 
Clinical Recommendations 
As documented above, for primary prevention,  
1. hsCRP is an independent predictor of future cardiovascular events that  
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2. Adds prognostic information to lipid screening, t 
3. To the metabolic syndrome,  
4. And to the Framingham Risk Score.  
In outpatient settings, the primary use of CRP should be at the time of 
cholesterol screening, when knowledge of CRP can be used as an adjunct for 
global risk assessment.(43) 
Goals of Screening and Therapeutic Options 
The primary goal of cardiovascular screening programs should be the 
identification of high-risk individuals who can be targeted for smoking 
cessation, diet, exercise, and blood pressure control. It is well established 
that compliance with lifestyle recommendations is directly related to the 
absolute risk perceived by individual patients. Thus, because the addition of 
CRP to lipid evaluation provides an improved prediction tool, consideration 
of CRP may have usefulness for this reason alone. There is currently no 
definitive evidence that lowering CRP will necessarily reduce cardiovascular 
event rates; studies addressing this issue are only now being designed. 
However, many interventions known to reduce cardiovascular risk have 
been linked to lower CRP levels. In particular, weight loss, diet, exercise, 
and smoking cessation all lead to both reduced CRP levels and reduced 
vascular risk. 
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Several pharmacological agents proven to reduce vascular risk 
influence CRP levels. Of these, the statin drugs are the most important, and 
studies with pravastatin, lovastatin, cerivastatin, simvastatin, and atorvastatin 
have all shown that, on average, median CRP levels decline 15% to 25% as 
early as 6 weeks after initiation of therapy. As shown in the large-scale 
Cholesterol And Recurrent Events (CARE)(46) and PRavastatin 
INflammation/CRP Evaluation (PRINCE)(45) trials and subsequently 
confirmed in other settings, there is little evidence that the magnitude of 
LDL reduction predicts the magnitude of CRP reduction. On the other hand,  
aggressive LDL reduction remains a critical therapeutic goal, and thus serial 
LDL evaluation should remain the primary method to monitor statin 
compliance. However, whereas all subjects taking statins achieve a 
beneficial reduction in LDL levels, there seems to be responders and non-
responders for statins in terms of CRP reduction. Whether this latter 
observation is important in terms of clinical event reduction is currently 
unknown. Analyses of 2 randomized trials suggest that the magnitude. 
Newer scopes for CRP as Therapeutic Target 
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Prospective treatments 
 CRP concentrations can be lowered by weight loss, exercise and 
treatment with statins or PPAR a/Y agonists [Circulation 105:564-9, 
Circulation 106:403-6, Circulation 103: 1933-5, Circulation 106: 679-84].  
Rosiglitazone therapy may improve CRP and other markers of CVD. 
A large-scale randomised clinical trial – Justification for the Use of Statins 
Primary Prevention: an Intervention Trial Evaluating Rosuvastatin 
(JUPITER) will test whether rosuvastatin will reduce cardiovascular disease 
in patients with elevated hs-CRP, who do not currently meet criteria for 
statin therapy. 
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MEDIATORS OF INFLAMMATION  
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AIM 
 
We set out to investigate the hypothesis that elevated C-reactive 
protein (CRP) levels a marker of an (altered immune response) 
inflammation, would correlate with coronary artery disease in patients with 
diabetic chronic renal disease. 
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MATERIAL AND METHODS 
This study is of Observational Study Design. Inclusive of a total 50 
patients. Between 2004 – 2006 at P.S.G.Institute of Medical Sciences and 
Research. 
AIM OF STUDY 
We set out to investigate the hypothesis that elevated C-reactive 
protein (CRP) levels a marker of an (altered immune response) 
inflammation, would correlate with coronary artery disease in patients with 
diabetic chronic renal disease. 
INCLUSION CRITERIA 
Patients with Stage 1 to stage 3 chronic kidney disease ( according to 
NKF- DOQI Guidelines)of Diabetic etiology  
Diabetes mellitus both type 1 and type 2 
EXCLUSION CRITERIA 
 Advanced stages of renal disease 
 Congestive cardiac failure 
 Hypoproteinemia 
 Inter current infection in the past 3 weeks 
 Connective tissue disorder. 
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PROFOMA 
Name  :          Age:       Sex: 
OP NO :          IP NO: 
Address : 
Ht  :         Wt :       BMI: 
DOA  :        DOD : 
Presenting complaint: 
Past H/O:     DM   yrs  
         HTN   yrs 
Personal H/O:   Smoking Y/N 
         If Y   yrs 
         Quantity  
         Alcohol  Y/N 
         If Y    yrs 
         Quantity 
Treatment H/O:   DM 
         SHT 
         OTHERS 
Family H/O:    DM / SHT / CAD / 
         Others 
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Examination: 
GC: 
Markers of CAD: 
PR:       BP: 
CVS:       
RS: 
GIT: 
CNS: 
ECG changes:   Y/N 
         If Y  
         AWMI    Y/N 
        IWMI     Y/N 
        RVMI     Y/N 
        LWMI     Y/N 
        PWMI     Y/N 
        Others 
TMT       +/-      L/M/H 
ECHO      EF: 
        RWMA    LAD 
               LSC 
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               RCA 
               Multiple 
        LV clot 
        MR 
Angio:  LMCA     N/Ab N 
         LAD      N/Ab N 
        Diagnols    N/Ab N 
        Septals     N/Ab N 
        LCX      N/Ab N 
        RCA      N/Ab N 
        Others 
 
 Blood Investigations: 
 FLP  : 
 hs CRP : 
 Sr.Creat : 
 HbA1C : 
 FBS  : 
 PPBS : 
 UA  : 
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CONSENT 
 
I, --------------------- exercise my free power of choice, hereby give my 
consent to be included in the study. I have been informed to my satisfaction 
by my attending doctor, the purpose of this study and the laboratory 
investigation that will be done with the sample obtained from me. I have 
been given the opportunity by the attending doctor to question on all aspects 
of the study and have understood the information given as a result. I hereby 
give permission for the doctor’s incharge of this study to release the results 
of study for academic purposes. 
 
 
Signature of the patient         Date: 
Signature of independent        Date: 
Witness            
 
I confirm that I have explained the nature and purpose of this study to 
my patients. 
                  
Signature of Doctor 
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RESULTS 
 
CHARACTERISTICS OF THE CASES AND THEIR 
RELATIONSHIP WITH CARDIOVASCULAR EVENTS 
 
There is no statistically significant between the mean age of patients 
with cardiovascular events and normal cases. 
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TABLE 1 
AGE AND CARDIOVASCULAR EVENTS 
 
Cardiovascular Events 
Yes No Age Group 
No. % No. % 
< 40 5 25 3 10 
41-50 4 20 7 23.3 
51-60 9 45 14 46.7 
>60 2 10 6 20 
Range 38-68 37-67 
Median 52 53 
Mean 50.4 53.3 
S.D. 9 8.1 
‘p’ 0.2755 
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TABLE 2 
SEX AND CARDIOVASCULAR EVENTS 
 
Cardiovascular Events 
Yes No Sex 
No. % No. % 
Male 15 75 25 83.3 
Female 5 25 5 16.7 
‘p’ 0.355 
 
  
The sex composition of the two groups does not have a statistically 
significant difference. 
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TABLE 3 
HBA 1C AND CARDIOVASCULAR EVENTS 
 
Cardiovascular Events 
Yes No HBA 1C 
No. % No. % 
Normal 7 35 27 90 
Abnormal 13 65 3 10 
‘p’ 0.0002 
 
 
 
  
The percentage of persons with abnormal HBA1C values is 
significantly higher in patients with cardiovascular events. 
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TABLE 4 
SMOKING AND CARDIOVASCULAR EVENTS 
 
Cardiovascular Events 
Yes No Smoking habit 
No. % No. % 
Yes 5 25 6 20 
No 15 75 24 80 
‘p’ 0.467 
 
 
  
Smoking habit and cardiovascular events do not have significant 
relationship. 
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TABLE 5 
HYPERTENSION AND CARDIOVASCULAR EVENTS 
 
Cardiovascular Events 
Yes No Hypertension 
No. % No. % 
Yes 16 80 22 73.3 
No 4 20 8 26.7 
‘p’ 0.4247 
 
 
 Hypertension and cardiovascular events do not have a statistically 
significant relationship. 
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TABLE 6 
LDL CHOLESTEROL AND CARDIOVASCULAR EVENTS 
 
Cardiovascular Events 
Yes No LDL Choles 
No. % No. % 
Normal 5 25 12 40 
Abnormal 15 75 18 60 
Range 
Median 
Mean 
S.D. 
38.7-190 
120 
127.9 
39.2 
70-170 
116 
112.2 
25.6 
P 0.1043 (Not Significant) 
 
Mean LDL Cholesterol values in abnormal patients and in normal 
cases do not differ significantly. 
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Table 7 
CRP and Cardiovascular events 
 
Cardiovascular Events 
Yes No CRP 
No. % No. % 
Normal - - 6 20 
Abnormal 20 100 24 80 
Range 
Median 
Mean 
S.D. 
3.43-15.7 
9.84 
9.48 
4.06 
2.8-10.3 
4.31 
5.15 
2.52 
P 0.0001 
 
 CRP Values are significantly higher in patients with cardiovascular 
events then in normal patients. This difference is statistically significant. 
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TABLE 8 
ECHO AND CARDIOVASCULAR EVENTS 
 
Cardiovascular Events 
Yes No ECHO 
No. % No. % 
Normal 5 25 22 73.3 
Abnormal 15 75 8 26.7 
‘p’ 0.0021 
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Statistical Tools 
Data collected in the questionnaire were tabulated in a master chart. 
Analysis of the data was done by using the software “Epidemiological 
Information Package Version 3.3.2, 2005” developed for World Health 
Organisation”. Frequencies, Percentages, Range, Median, Mean, Standard 
Deviation and ‘p’ values were calculated using this package. 
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DISSCUSSION 
 
1) Our data suggest that the elevated C-reactive protein level is a predictor 
of cardiovascular events in Diabetic Renal Disease population. Unlike 
other markers of inflammation (ICAM, IL-6etc), C-reactive protein 
levels are stable over long periods, have no diurnal variation, can be 
measured inexpensively with available high-sensitivity assays, and have 
shown specificity in terms of predicting the risk of cardiovascular 
disease.24, 28, 29, 30 
2) C-reactive protein is a stronger predicter of cardiovascular events than 
the LDL cholesterol level. The same was suggested by Paul M Ridker 
and Co-workers and several other workers also and our study 
demonstrates the same observation(33).THE addition of crp to standard 
cholesterol evaluation may thus provide a effective and inexpensive and 
non invasive method to improve clobal risk prediction and compliance 
with approaches. 
3) Tighter glycemic controls are associated with better cardiovascular 
outcomes.  
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CONCLUSION 
 
 CRP level is independently associated with Coronary artery disease in 
our study group of Diabetic CKD patients and is useful predictive marker for 
Cardiovascular events(IHD)in the study population. 
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ABBREVIATIONS  
 
CVD  - Cardio Vascular Disease 
CAD  - Coronary Artery Disease 
DM  - Diabetes Mellitus 
ESRD - End Stage Renal Disease 
hs CRP - Highly sensitive C- Reactive protein 
CIMT - Carotid Intimal Medial Thickening 
CKD  - Chronic Kidney Disease 
LVH  - Left Ventricular Hypertrophy 
IHD  - Ischemic Heart Disease 
PVD   - Peripheral Vascular Disease 
HF  - Heart Failure 
LDL   - Low Density Lipoprotein 
HTN  - Hypertension  
AWMI - Anterior Wall Myocardial Infarction  
IW  - Inferior Wall  
RV  - Right Ventricle 
RWMA - Regional Wall Motion Abnormality 
TMT   - Tread Mill Test  
LV   - Left Ventricle  
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MR  Mitral Regurgitation  
LMCA Left Main Circumflex Artery  
LAD  Left Anterior Descending 
LCX  Left Circumflex  
RCA  Right Circumflex Artery  
FLP   Fasting Lipid Profile  
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